Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission

References

• Nishiwaki S, Inamoto Y, Imamura M, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission. Blood. 2011;117(13):3698–3699.
   PubMed Web of Science ®Google Scholar
• Stefan F, Susan O’ B, Ching-Hon P, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010;116(5):1165–1176.
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Atsuta Y, Tanaka J. Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available? Bone Marrow Transplant. 2013;48(11):1369–1376.
   PubMed Web of Science ®Google Scholar
• Raiola AM, Dominietto A, di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20(10):1573–1579.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956–3962.
   PubMed Web of Science ®Google Scholar
• Luo Y, Xiao H, Lai X, et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood. 2014;124(17):2735–2743.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767.
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Inamoto Y, Sakamaki H, et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood. 2010;116(20):4368–4375.
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Miyamura K, Ohashi K, et al. Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Ann Oncol. 2013;24(6):1594–1602.
   PubMed Web of Science ®Google Scholar
• Mo X-D, Xu L-P, Zhang X-H, et al. Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: No difference in the high- and low-risk groups. Int J Cancer.. 2015;136(7):1697–1707.
   PubMed Web of Science ®Google Scholar
• Lee S, Chung NG, Cho BS, et al. Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia negative acute lymphoblastic leukemia. Leukemia. 2010;24(12):2110–2119.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Laura EL, Sandhyarani D, Qing C, et al. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graftsource and survival. Bone Marrow Transplant. 2015;50(11):1432–1437.
   PubMed Web of Science ®Google Scholar
• Dropulic LK, Jones RJ. Polyomavirus Bk Infection in Blood and Marrow Transplant Recipients. Bone Marrow Transplant. 2008; 41(1):11–18.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695–706.
   PubMed Web of Science ®Google Scholar
• Silva L.DP, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity, and donor type. Haematologica. 2010;95(7):1183–1190.
   PubMed Web of Science ®Google Scholar
• Pidala J, Djulbegovic B, Anasetti C, et al. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2011;10:CD008818.
   Google Scholar
• Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827–1833.
   PubMed Web of Science ®Google Scholar
• Yan CH, Jiang Q, Wang J, et al. Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant. 2014;20 (9):1314–1321.
   PubMed Web of Science ®Google Scholar
• Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065–3073.
   PubMed Web of Science ®Google Scholar
• Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112(9):3574–3581.
   PubMed Web of Science ®Google Scholar
• Rabbitts TH, Forster A, Larson R, et al. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet. 1993;4(2):175–180.
   PubMed Web of Science ®Google Scholar
• Nobbs MC, Chan-Lam D, Howell RT, et al. Acute nonlymphocytic leukemia with t(16;21). Cancer Genet Cytogenet. 1993;70(2):144–145.
   PubMedGoogle Scholar
• Pan J, Zou J, Wu DY, et al. TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells. Mol Cancer Res. 2008;6(5):862–872.
   PubMed Web of Science ®Google Scholar
• Kanazawa T, Ogawa C, Taketani T, et al. TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease. Leuk Lymphoma. 2005;46(12):1833–1835.
   PubMed Web of Science ®Google Scholar
• Oh SH, Park TS, Choi JR, et al. Two childhood cases of acute leukemia with t(16;21)(p11.2;q22): second case report of infantile acute lymphoblastic leukemia with unusual type of FUS-ERG chimeric transcript. Cancer Genet Cytogenet. 2010;200(2):180–183.
   PubMedGoogle Scholar
• Pan J, Zhang Y, Zhao YL, et al. Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene. Leuk Lymphoma. 2017;58(7):1655–1663.
   PubMed Web of Science ®Google Scholar
• von Lindern M, van Baal S, Wiegant J, et al. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol Cell Biol. 1992;12 (8):3346–3355.
   PubMed Web of Science ®Google Scholar
• Ichijo T, Chrousos GP, Kino T. Activated glucocorticoid receptor interacts with the INHAT component Set/TAF-Iβ and releases it from a glucocorticoid responsive gene promoter, relieving repression: implications for the pathogenesis of glucocorticoid resistance in acute undifferentiated leukemia with Set-Can translocation. Mol Cell Endocrinol. 2008;283(1-2):19–31.
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Mancini M, et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol. 2003;120(3):484–487.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Malagola M, Rondoni M, et al. Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. Leuk Lymphoma. 2006;47(3):469–472.
   PubMed Web of Science ®Google Scholar
• Kaneko H, Misawa S, Horiike S, et al. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood. 1995;85(8):2189–2193.
   PubMed Web of Science ®Google Scholar
• Qian M, Cao X, Devidas M, et al. TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36(6):591–599.
   PubMed Web of Science ®Google Scholar
• Comeaux EQ, Mullighan CG. TP53 mutations in hypodiploid acute lymphoblastic leukemia. Cold Spring Harb Perspect Med. 2017;7(3):a026286.
   PubMed Web of Science ®Google Scholar
• Neri A, Knowles DM, Greco A, et al. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA. 1988;85(23):9268–9272.
   PubMed Web of Science ®Google Scholar
• Giménez N, Martínez-Trillos A, Montraveta A, et al. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica. 2019;104(3):576–586.
   PubMed Web of Science ®Google Scholar
• Vendramini E, Bomben R, Pozzo F, et al. KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia. 2019;33(8):2111–2115.
   PubMed Web of Science ®Google Scholar
• Al Sarakbi W, Sasi W, Jiang WG, et al. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. BMC Cancer. 2009;9:290.
   PubMed Web of Science ®Google Scholar
• Mar BG, Bullinger LB, McLean KM, et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014;5(1):3469.
   PubMedGoogle Scholar
• McKinney M, Moffitt AB, Gaulard P, et al. The genetic basis of hepatosplenic T-cell lymphoma. Cancer Discov. 2017;7(4):369–379.
   PubMed Web of Science ®Google Scholar
• Mar BG, Haihua Chu S, Kahn JD, et al. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. 2017;130(24):2631–2641.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang C, Gao L, et al. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China. J Hematol Oncol. 2015;8(1):90.
   PubMedGoogle Scholar
• Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20(12):1975–1981.
   PubMed Web of Science ®Google Scholar
• Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001;98(10):2900–2908.
   PubMed Web of Science ®Google Scholar
• Pan L, Delmonte J, Jr, Jalonen CK, et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces the severity of experimental graft-versushost disease. Blood. 1996;86:4422–4429.
   Google Scholar